Severe impairment of postprandial cholecystokinin release and gall‐bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR
Abstract
Background Acromegalic patients treated three times daily with subcutaneous injections of the somatostatin analogue octreotide frequently develop gallstones, due to suppressed cholecystokinin release and impaired gall-bladder emptying. Aim To elucidate the effects of a new long-acting octreotide formulation (Sandostatin LAR) on gall-bladder emptying, cholecystokinin release and gallstone formation. Methods Postprandial gall-bladder and gastric emptying were determined by ultrasonography and cholecystokinin release was measured in seven patients on days 0, 14, 28, and 75 (Sandostatin LAR, 20 mg intramuscularly on days 1, 30, and 60). Results During treatment, fasting gall-bladder volumes increased from 26.5 +/- 3.2 mL to 61.4 +/- 7.5 mL, but postprandial cholecystokinin release and gall-bladder emptying (from 63.9 +/- 3.8% to 12.3 +/- 3.5%) were severely suppressed. Gallstones formed in six out of seven patients within 8 months of treatment. Gastric emptying did not change during the therapy. Conclusions The risk of gallstone formation is greatly increased during Sandostatin LAR. This is probably related to profound suppression of cholecystokinin release and gall-bladder emptying.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Gallstone formation may influence treatment selection for dumping syndrome.
“Gallstone formation may influence treatment selection for dumping syndrome (96,97).”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [97]
Cited by
Sorted by citations
Portincasa, P., Moschetta, A., & Palasciano, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69044-2 · Cited by 770 · see citing works
Self-citationEASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones
Lammert, F., Acalovschi, M., Ercolani, G., van Erpecum, K. V., Gurusamy, K., van Laarhoven, C. V., & Portincasa, P. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.005 · Cited by 667 · see citing works
Self-citationLammert, F., Gurusamy, K., Ko, C. W., Miquel, J., Méndez-Sánchez, N., Portincasa, P., van Erpecum, K. V., van Laarhoven, C. V., & Wang, D. Q. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.24 · Cited by 405 · see citing works
Self-citationPathophysiology, diagnosis and management of postoperative dumping syndrome
Tack, J., Arts, J., Caenepeel, P., De Wulf, D., & Bisschops, R. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.148 · Cited by 387 · see citing works
“Gallstone formation is not an uncommon complication of the long-term use of somatostatin analogs and should be taken into account when considering treatment options for dumping syndrome”
BackgroundMarschall, H., & Einarsson, C. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01783.x · Cited by 204 · see citing works
van Beek, A. P., Emous, M., Laville, M., & Tack, J. (2017) · Obesity Reviews · doi:10.1111/obr.12467 · Cited by 288 · see citing works
“Gallstone formation may influence treatment selection for dumping syndrome (96,97).”
BackgroundHousset, C., Chrétien, Y., Debray, D., & Chignard, N. (2016) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2016.tb00717.x · Cited by 173 · see citing works
“In patients most often treated for acromegaly, the somatostatin analog, octreotide, causes severe impairment of gallbladder emptying, and inhibits the postprandial release of CCK (165).”
Coordinate regulation of gallbladder motor function in the gut‐liver axis
Portincasa, P., Ciaula, A. D., Wang, H. H., Palasciano, G., van Erpecum, K. V., Moschetta, A., & Wang, D. Q. (2008) · Hepatology · doi:10.1002/hep.22204 · Cited by 143 · see citing works
Self-citationArts, J., Caenepeel, P., Bisschops, R., Dewulf, D., Holvoet, L., Piessevaux, H., Bourgeois, S., Sifrim, D., Janssens, J., & Tack, J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.11.025 · Cited by 142 · see citing works
Management of gallstones and its related complications
Portincasa, P., Ciaula, A. D., de Bari, O., Garruti, G., Palmieri, V. O., & Wang, D. Q. H. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1109445 · Cited by 141 · see citing works
“[1] Long-term therapy with somatostatin or analogues significantly increases gallstone formation by inducing biliary lithogenicity and gastrointestinal motility defects, including delayed intestinal transit and gallbladder stasis.[163,164] In these patients, UDCA prophylactic therapy has been suggested.”
BackgroundSelf-citationLustig, R. H., Greenway, F., Velásquez-Mieyer, P. A., Heimburger, D., Schumacher, D., Smith, D. K., Smith, W., Soler, N., Warsi, G., Berg, W., et al. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803074 · Cited by 104 · see citing works
Symptoms and diagnosis of gallbladder stones
Portincasa, P., Moschetta, A., Petruzzelli, M., Palasciano, G., Ciaula, A. D., & Pezzolla, A. (2006) · doi:10.1016/j.bpg.2006.05.005 · Cited by 93
Self-citationÖberg, K., & Lamberts, S. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-16-0151 · Cited by 90 · see citing works
“Altered secretion of cholecystokinin can lead to abnormalities in the biliary system (Moschetta et al. 2001).”
BackgroundParkinson, C., Drake, W. M., Roberts, M. E., Meeran, K. M., BESSER, G. M., & Trainer, P. J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8432 · Cited by 90 · see citing works
Smooth muscle function and dysfunction in gallbladder disease
Portincasa, P., Ciaula, A. D., & vanBerge-Henegouwen, G. (2004) · Current Gastroenterology Reports · doi:10.1007/s11894-004-0043-0 · Cited by 77 · see citing works
Self-citationGastrointestinal symptoms and motility disorders in patients with systemic scleroderma
Ciaula, A. D., Covelli, M., Berardino, M., Wang, D. Q., Lapadula, G., Palasciano, G., & Portincasa, P. (2008) · BMC Gastroenterology · doi:10.1186/1471-230x-8-7 · Cited by 75 · see citing works
“However, also taking into account the altered gallbladder refilling noticed in SSc patients, this therapeutic option should be considered with caution, since the long-acting octreotide formulation has been shown to greatly increase the risk of gallstone formation probably by suppression of endogenous cholecystokinin r…”
BackgroundSelf-citationHereditary liver disease: gallstones.
Wittenburg, H. (2010) · Best practice & research. Clinical gastroenterology · doi:10.1016/j.bpg.2010.07.004 · Cited by 62
Gallstone disease: Primary and secondary prevention.
Venneman, N. G., & van Erpecum, K. V. (2006) · Best practice & research. Clinical gastroenterology · doi:10.1016/j.bpg.2006.03.008 · Cited by 62 · see citing works
Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism
Moyes, V., Monson, J., Chew, S., & Akker, S. (2010) · International Journal of Endocrinology · doi:10.1155/2010/906163 · Cited by 61
Attanasio, R., Mainolfi, A., Grimaldi, F., Cozzi, R., Montini, M., Carzaniga, C., Grottoli, S., Cortesi, L., Albizzi, M., Testa, R., et al. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346419 · Cited by 60 · see citing works
Octreotide LAR: safety and tolerability issues
Bornschein, J., Drozdov, I., & Malfertheiner, P. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903379525 · Cited by 56
“The incidence of new bile stones in patients without pathological findings in the biliary system at baseline was 5 – 66% under long-term treatment with octreotide LAR [2,47,53,55-57,63,96,97].”
BackgroundProphylactic Cholecystectomy in Midgut Carcinoid Patients
Norlén, O., Hessman, O., Stålberg, P., Åkerström, G., & Hellman, P. (2010) · World Journal of Surgery · doi:10.1007/s00268-010-0428-1 · Cited by 55 · see citing works
“emptying and inhibit relaxation of sphincter oddi, lead to enhanced gallstone formation [2–7].”
BackgroundOctreotide therapy in dumping syndrome: analysis of long‐term results
Didden, P., Penning, C., & Masclee, A. (2006) · Alimentary Pharmacology and Therapeutics · doi:10.1111/j.1365-2036.2006.03124.x · Cited by 52 · see citing works
Physiology and Pathophysiology of the Biliary Tract: The Gallbladder and Sphincter of Oddi—A Review
Behar, J. (2013) · doi:10.1155/2013/837630 · Cited by 47
Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?
Varannes, S. B. D., Coron, E., & Galmiche, J. (2010) · Best practice & research. Clinical gastroenterology · doi:10.1016/j.bpg.2010.09.004 · Cited by 47 · see citing works
Octreotide Long-Acting Release (LAR)
McKeage, K., Cheer, S., & Wagstaff, A. (2012) · Drugs · doi:10.2165/00003495-200363220-00014 · Cited by 47 · see citing works
Adverse events associated with somatostatin analogs in acromegaly
Grasso, L., Auriemma, R., Pivonello, R., & Colao, A. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1059817 · Cited by 42
“SSA further increase intestinal and biliary production of deoxycholic acid and cholesterol saturation, all promoting the nucleation of cholesterol crystals and their aggregation into stones [72-74].”
BackgroundBrighi, N., Lamberti, G., Maggio, I., Manuzzi, L., Ricci, C., Casadei, R., Santini, D., Mosconi, C., Lisotti, A., Ambrosini, V., et al. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.09.013 · Cited by 41
Paisley, A., Roberts, M., & Trainer, P. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02811.x · Cited by 35 · see citing works
Measurements of gallbladder motor function by ultrasonography: towards standardization.
Portincasa, P., Moschetta, A., Colecchia, A., Festi, D., & Palasciano, G. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00096-3 · Cited by 34
Self-citationCombined treatment of somatostatin analogues with pegvisomant in acromegaly
Franck, S. E., Muhammad, A., van der Lely, A. J., & Neggers, S. (2015) · Endocrine · doi:10.1007/s12020-015-0810-8 · Cited by 29 · see citing works
Behar, J., Mawe, G., & Carey, M. (2013) · Neurogastroenterology and Motility · doi:10.1111/nmo.12094 · Cited by 26
Marciani, L., Coleman, N., Dunlop, S., Singh, G., Marsden, C., Holmes, G., Spiller, R., & Gowland, P. (2005) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.20436 · Cited by 20 · see citing works
Rehfeld, J., Federspiel, B., Agersnap, M., Knigge, U., & Bardram, L. (2016) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2016.1183706 · Cited by 19 · see citing works
“Regarding the bilestones of the patient, it is possible that the octreotide treatment contributed to their occurrence.[36] A broader aspect of the CCKoma syndrome is that the hyperCCKemia originated almost entirely from the liver metastases, not from the primary pancreatic tumor.”
BackgroundSelf-citationFactors affecting gallbladder motility: drugs.
Marzio, L. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00088-4 · Cited by 19 · see citing works
Preventing a Mass Disease: The Case of Gallstones Disease: Role and Competence for Family Physicians
Portincasa, P., Ciaula, A. D., & Grattagliano, I. (2016) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2016.37.4.205 · Cited by 16 · see citing works
“Patients on long-term therapy with somatostatin or analogues: These patients exhibit biliary lithogenic changes and gastrointestinal motility changes, including delayed intestinal transit and gallbladder stasis [66,67].”
BackgroundSelf-citationPrencipe, N., Bona, C., Cuboni, D., Parasiliti-Caprino, M., Berton, A., Fenoglio, L., Gasco, V., Ghigo, E., & Grottoli, S. (2020) · Pituitary · doi:10.1007/s11102-020-01102-7 · Cited by 15
Aapkes, S., de Haas, R. D., Bernts, L., Blijdorp, C., Dekker, S., van Gastel, M. D. A., Meijer, E., Veldman, A., Drenth, J., Gansevoort, R., et al. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00342-7 · Cited by 14 · see citing works
Moschetta, A., Twickler, T., Rehfeld, J., van Ooteghem, N. A. V., Cabezas, M., Portincasa, P., van Berge-Henegouwen, G. P., & van Erpecum, K. V. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000020515.75879.2f · Cited by 14
“Gallbladder motility is impaired during octreotide therapy, whether administered by intermittent subcutaneous injection, continuous subcutaneous infusion, or intramuscular depot injection (6, 7).”
BackgroundSelf-citationCozzi, R. C., & Attanasio, R. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.2.129 · Cited by 14 · see citing works
Portincasa, P., Moschetta, A., & Palasciano, G. (2002) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32170-2 · Cited by 12
Self-citationIncidence of gall stone formation in acromegalic patients on octreotide therapy
Chakravarty, A. A., Ajmani, A. K., Manchanda, S., Kulshreshtha, B., & Chopra, S. (2012) · Indian journal of endocrinology and metabolism · doi:10.4103/2230-8210.95683 · Cited by 10
“[12] However, another study reported a very high incidence of gallstones in six out of seven patients within 8 months of therapy.[13] Serial ultrasound scanning at 6-month interval for formation and progression of gall stones on somatostatin analogs was performed by Ayuk et al.”
BackgroundMethodMawe, G., Moses, P., Saccone, G., & Pozo, M. (2009) · doi:10.1002/9781444303254.ch12 · Cited by 10
Octreotide long-acting repeatable for acromegaly
Cozzi, R. C., & Attanasio, R. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.4 · Cited by 9 · see citing works
Telocytes: New Players in Gallstone Disease.
Pasternak, A., Gil, K., & Matyja, A. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-1061-3_5 · Cited by 9
Ultrasonographic assessment of gastric and gallbladder dynamics in human health and disease
Ciaula, A. D., Khalil, M., & Portincasa, P. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-03905-7 · Cited by 8 · see citing works
“…as prokinetics or anti-spasmodics, or producing additional effects on stomach/ gallbladder while treating systemic diseases, such as somatostatin [17] or GLP1-agonists [18, 19] which have investigated looking at gastric and gallbladder motility [20] and of satiety in the context of the gut–brain…”
Self-citationGallbladder motility and gut hormone plasma levels in subjects with and without gallstones.
Montet, J., Caroli-Bosc, F., Ferrari, P., Piche, T., Baize, N., Anty, R., Montet, A., Rampal, P., & Tran, A. (2005) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(05)82131-1 · Cited by 8
“Similarly, large doses of the somatostatin analogue given to acromegalic patients, impaired gallbladder emptying and probably explain the high incidence of gallstones in these patients [24].”
BackgroundOctreotide increases the proportions of arachidonic acid‐rich phospholipids in gall‐bladder bile
Pereira, S., Hussaini, S., Murphy, G. M., Wass, J., & Dowling, R. (2001) · Alimentary Pharmacology and Therapeutics · doi:10.1046/j.1365-2036.2001.01077.x · Cited by 8
Pathophysiology of cholesterol gallstone disease
Portincasa, P., Moschetta, A., Ciaula, A. D., Pontrelli, D., Sasso, R. C., Wang, H. H., & Wang, D. Q. (2008) · doi:10.1007/978-88-470-0763-5_3 · Cited by 8
Self-citationSomatostatin Receptor PET/CT Features of Carcinoid Heart Disease.
Arora, S., Passah, A., Damle, N., Narang, R., Sharma, A., Yadav, M., Ballal, S., Bhasin, D., & Bal, C. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002139 · Cited by 6
Hormonale und metabolische Funktionen des Dünndarms
Wittenburg, H., Tennert, U., & Mössner, J. (2010) · Der Internist · doi:10.1007/s00108-009-2564-y · Cited by 6 · see citing works
Tai, M.-H., Chen, L., He, Y.-J., Wang, F., & Tian, Z. (2024) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-023-06209-w · Cited by 5
“Ultrasonography can also be used to evaluate the effect of other medications that may affect gallbladder motility [22].”
BackgroundHan, Z.-H., He, Z.-M., Chen, W.-H., Wang, C.-Y., & Wang, Q. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i25.7484 · Cited by 4
Ye, W., & Liu, Z. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178053 · Cited by 1 · see citing works
Polowczyk, B., Kałużny, M., & Bolanowski, M. (2020) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.3056 · Cited by 1 · see citing works
Medication and Diet in Gallstone Diseases
Cha, S. (2014) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2014.19.4.164 · Cited by 1 · see citing works
Motricite vésiculaire et oddienne : physiologie et physiopathologie
Vitton, V., Grimaud, J., & Barthet, M. (2007) · doi:10.1016/s1155-1976(07)40556-3 · Cited by 1
The non-surgical therapy of uncomplicated gallbladder stones: is there a niche?
Sauerbruch, T., & Lammert, F. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2656233
Physiopathologie, épidémiologie et histoire naturelle de la lithiase biliaire
Hedjoudje, A., & Prat, F. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)46521-8
Dumping syndrome following bariatric surgery: an update
Mettananda, C., & Shah, P. (2025) · Journal of the Ceylon College of Physicians · doi:10.4038/jccp.v56i2.8109
“21 Furthermore, the effects of somatostatin analogues may not be sustained for long.”
Jiao, J.-Y., Zhu, X.-J., Zhou, C., & Wang, P. (2022) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v14.i9.887
Biliary Tract Disorders in Patients with Acromegaly: Single-centre Experience
Sendur, S., & Oğuz, S. (2022) · Acta medica · doi:10.32552/2022.actamedica.774
Lobo, M. D. (2020) · Postural Tachycardia Syndrome · doi:10.1007/978-3-030-54165-1_32
Genetic Predisposition to Gallbladder Stones
Wittenburg, H., & Lammert, F. (2007) · doi:10.1055/s-2006-960174
“However, somatostatin and octreotide inhibit postprandial CCK release from the gastrointestinal tract, and an important role of CCK and its receptor in gallstone formation is underscored by high gallstone prevalence rates in patients with somatostatinoma(78) and in patients treated with octreotide.(79) Further support…”
Spotlight on Octreotide Long-Acting Release (LAR) in Acromegaly
McKeage, K., Cheer, S., & Wagstaff, A. (2004) · doi:10.2165/00024677-200403030-00007
Pak, K. H., & Noh, S. H. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2223-9_13
“Gallstone formation is not an uncommon complication of the long-term use of somatostatin analogs and should be taken into account when considering treatment options for dumping syndrome [37, 38].”
Background
- Authors
- Moschetta, A., Stolk, M. F. J., Rehfeld, J. F., Portincasa, P., Slee, P. H. T. J., Koppeschaar, H. P. F., Van Erpecum, K. J., & Vanberge‐Henegouwen, G. P.
- Affiliations
- University Medical Center Utrecht (NL)
- St. Antonius Ziekenhuis (NL)
- Copenhagen University Hospital (DK)
- University of Bari Aldo Moro (IT)
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2001-02-05
- Volume
- 15
- Issue
- 2
- Pages
- 181-185
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2090945605
- Cited by
- 79
- References
- 0
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 2 · 2016: 9 · 2015: 7 · 2014: 2 · 2013: 2 · 2012: 2
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gallbladder and Bile Duct Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- acromegaly, gallstone formation, cholecystokinin release, gallbladder emptying, octreotide, Sandostatin LAR, long-acting somatostatin analogue, gastric emptying, gallbladder volume
- MeSH terms
- Acromegaly, Aged, Aged, 80 and over, Chemistry, Pharmaceutical, Cholecystokinin, Cholelithiasis, Female, Gastrointestinal Agents, Humans, Male, Middle Aged, Risk Factors, Octreotide, Gallbladder Emptying, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
